research Unraveling the Secret Life of the Hair Follicle: From Fungi to Innovative Hair Loss Therapies
New hair loss treatments have evolved from understanding hair biology and patient needs.
Search
for
Sort by
Research
330-360 / 1000+ results research SnapshotDx Quiz: April 2022
Discoid Lupus Erythematosus causes scalp plaques that can lead to hair loss, and antimalarial drugs are effective treatments.
research New Treatment Strategies in Management of Alopecia Areata: A Review Article
New treatments for sudden hair loss include oral medications and a special laser, both showing promise in hair regrowth.
research Therapeutic Advances in Trichology
Recent advances in hair loss treatments show significant progress.
research Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research Response to Effectiveness of Dutasteride in a Large Series of Patients with Frontal Fibrosing Alopecia in Real Clinical Practice
The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.
research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
research Novel Potential Therapeutic Targets of Alopecia Areata
New treatments for hair loss from alopecia areata may include targeting immune cells, using stem cells, balancing gut bacteria, applying fatty acids, and using JAK inhibitors.
research Effectiveness of Oral Tofacitinib Treatment on Patients With Moderate-to-Severe Alopecia Areata in Iran
Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
research Medical Therapies
Combination therapies might work better for some vitiligo patients, but results vary.
research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Retrospective Cohort Study of 90 Patients
Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
research Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
research Latest Understanding and Treatment of Alopecia Areata
New treatments for alopecia areata, like JAK inhibitors and immunomodulators, are promising.
research PSS20 Mediation Modeling and Measurement Characteristics of the Itch Severity Score from a Phase 2B Trial of Oral CP-690-550 in Patients with Moderate-to-Severe Plaque Psoriasis
CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
research The Experts Meetings on Psoriasis: Recommendations for Daily Practice
Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata
Topical JAK inhibitors may help children with alopecia areata regrow hair.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research Treating Alopecia Areata: Current Practices Versus New Directions
New treatments like JAK inhibitors show promise for reversing alopecia areata.
research Alopecia Areata: An Update on Treatment Options for Children
Individualized treatment plans are crucial for children with alopecia areata, with promising options like JAK inhibitors showing significant hair regrowth.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Alopecia Areata: A Review of the Role of Oxidative Stress, Possible Biomarkers, and Potential Novel Therapeutic Approaches
Oxidative stress plays a significant role in alopecia areata, and new treatments may include JAK inhibitors and antioxidants.
research Rethinking The Classification Of Alopecia Areata
The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
research Topical Tofacitinib for the Treatment of Alopecia Areata Affecting Facial Hair
Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
research Alopecia Areata Flare Patterns in Children and Young Adults on Systemic Tofacitinib
Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
research Alopecia Areata: Medical Treatments
Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.
research Design and Characterization of Baricitinib Incorporated PLA 3D Printed Pills by Fused Deposition Modeling for Treating Alopecia Areata
The study created 3D-printed pills that effectively release a hair loss treatment drug over 24 hours.
research Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
JAK inhibitors show promise for treating various skin diseases.
research Alopecia Universalis: Partial Response to Tofacitinib
Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
research Janus Kinase Inhibitors for the Use of Alopecia Areata: A Promising Therapeutic of the Future
JAK inhibitors show promise as a future treatment for hair loss.
research Treatment of Severe Alopecia Areata with Oral Tofacitinib: A Case Series
Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.